We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+9.96%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.79B
AUM Growth
-$56M
Cap. Flow
-$584M
Cap. Flow %
-20.93%
Top 10 Hldgs %
31.86%
Holding
129
New
19
Increased
19
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$67.9M
2
XENT
Intersect ENT, Inc
XENT
+$33.9M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$32.9M
4
NVRO
NEVRO CORP.
NVRO
+$32.8M
5
ACHC icon
Acadia Healthcare
ACHC
+$27.2M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$130M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$80M
3
AET
Aetna Inc
AET
+$42M
4
CVS icon
CVS Health
CVS
+$39.3M
5
WBA
Walgreens Boots Alliance
WBA
+$31.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.65%
2 Financials 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
26
Universal Health Services
UHS
$9.12B
$33.5M 1.2%
262,000
– –
IMMU
27
DELISTED
Immunomedics Inc
IMMU
$33.1M 1.19%
1,590,000
+465,200
+41% +$11M
NVRO
28
DELISTED
NEVRO CORP.
NVRO
$29.9M 1.07%
+525,040
New +$32.8M
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.91B
$29.2M 1.05%
260,064
+95,064
+58% +$10M
SEM
30
DELISTED
Select Medical
SEM
$28.1M 1.01%
2,832,256
-616,192
-18% -$6.38M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$4.84B
$27.1M 0.97%
1,061,956
-164,934
-13% -$3.21M
AGIO icon
32
Agios Pharmaceuticals
AGIO
$2.38B
$26.9M 0.96%
348,200
-1,800
-0.5% -$145K
ELV icon
33
Elevance Health
ELV
$83.4B
$26M 0.93%
95,000
-96,000
-50% -$24.9M
DFBHU
34
DELISTED
DFB Healthcare Acquisitions Corp. Unit
DFBHU
$25.5M 0.91%
2,500,000
– –
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$24M 0.86%
294,000
-315,554
-52% -$22.2M
VCEL icon
36
Vericel Corp
VCEL
$2.35B
$22.9M 0.82%
+1,617,730
New +$19M
ASND icon
37
Ascendis Pharma A/S
ASND
$16.6B
$22.7M 0.81%
320,000
-162,467
-34% -$11.2M
ARVN icon
38
Arvinas
ARVN
$516M
$20.8M 0.75%
+1,233,734
New +$20.3M
RGNX icon
39
Regenxbio
RGNX
$577M
$20.8M 0.74%
275,000
+150,000
+120% +$10.8M
BOLD
40
DELISTED
Audentes Therapeutics, Inc
BOLD
$19.6M 0.7%
493,901
-554,529
-53% -$20.7M
SYBX
41
DELISTED
Synlogic
SYBX
$19.4M 0.69%
91,010
– –
FATE icon
42
Fate Therapeutics
FATE
$325M
$19.1M 0.68%
+1,173,617
New +$13.9M
EPZM
43
DELISTED
Epizyme, Inc
EPZM
$18.9M 0.68%
1,779,094
+140,094
+9% +$1.6M
OXFD
44
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$17.6M 0.63%
1,087,359
-223,641
-17% -$3.2M
DPLO
45
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$16.6M 0.59%
+853,687
New +$18.2M
MOR
46
DELISTED
MorphoSys AG American Depositary Shares
MOR
$16M 0.57%
600,000
– –
ZBH icon
47
Zimmer Biomet
ZBH
$17.4B
$15.9M 0.57%
124,630
– –
ARDX icon
48
Ardelyx
ARDX
$1.28B
$15.2M 0.54%
3,491,922
– –
SYRS
49
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$15.1M 0.54%
126,895
– –
AIMT
50
DELISTED
Aimmune Therapeutics
AIMT
$15.1M 0.54%
553,000
-120,000
-18% -$3.39M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2018 Portfolio in Review

As of Q3 2018, Deerfield Management held 129 positions worth $2.79B, down 2% from $2.85B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $584M in Q3 2018, closing 26 positions and reducing 27 holdings. Its most notable exit was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $130M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 74% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $29.9M.

  • Deerfield Management's largest Q3 2018 buy was NEVRO CORP.: 525,040 shares worth $29.9M.
  • Deerfield Management added most to Aerie Pharmaceuticals in Q3 2018, an estimated $67.9M increase.
  • Deerfield Management's biggest Q3 2018 reduction was Tandem Diabetes Care, cutting an estimated $80M.
  • Deerfield Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q3 2018, selling an estimated $130M.
  • Deerfield Management's ten largest holdings make up 32% of its $2.79B portfolio in Q3 2018.
  • Deerfield Management opened 19 new positions and closed 26 in Q3 2018.
  • Deerfield Management's portfolio value fell 2% quarter-over-quarter to $2.79B.

Based on Deerfield Management's 13F filing for Q3 2018, filed 14 Nov 2018.